Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167


Nkx3.1 controls the DNA repair response in the mouse prostate.

Zhang H, Zheng T, Chua CW, Shen M, Gelmann EP.

Prostate. 2016 Mar;76(4):402-8. doi: 10.1002/pros.23131. Epub 2015 Dec 10.


Treatment of the Prostate in the Presence of Metastases: Lessons from Other Solid Tumors.

Neugut AI, Gelmann EP.

Eur Urol. 2016 May;69(5):795-6. doi: 10.1016/j.eururo.2015.06.004. Epub 2015 Jun 19. No abstract available.


NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.

Bowen C, Zheng T, Gelmann EP.

Cancer Res. 2015 Jul 1;75(13):2686-98. doi: 10.1158/0008-5472.CAN-14-3387. Epub 2015 May 14.


The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.

Song LN, Silva J, Koller A, Rosenthal A, Chen EI, Gelmann EP.

Mol Cancer Res. 2015 May;13(5):913-22. doi: 10.1158/1541-7786.MCR-14-0680. Epub 2015 Mar 16.


Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer.

Muhlbradt E, Ma J, Severi G, Ortner E, Hayes V, Hoang HN, Stampfer M, Giles G, Pollak M, Gelmann EP.

Genes Cancer. 2013 Nov;4(11-12):535-45. doi: 10.1177/1947601913506009.


Functional activation of ATM by the prostate cancer suppressor NKX3.1.

Bowen C, Ju JH, Lee JH, Paull TT, Gelmann EP.

Cell Rep. 2013 Aug 15;4(3):516-29. doi: 10.1016/j.celrep.2013.06.039. Epub 2013 Jul 25.


Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I.

Song LN, Bowen C, Gelmann EP.

Biochem J. 2013 Jul 1;453(1):125-36. doi: 10.1042/BJ20130012.


Renal cell cancer treated with a single-edged sword.

Lim E, Gelmann EP.

Cell Rep. 2013 Feb 21;3(2):275-6. doi: 10.1016/j.celrep.2013.02.001.


High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.

Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, Terracciano LM, Bachmann A, Wyler S, Bubendorf L, Rentsch CA.

Prostate. 2012 Nov;72(15):1678-87. doi: 10.1002/pros.22521. Epub 2012 Apr 2.


NKX3.1 activates cellular response to DNA damage.

Bowen C, Gelmann EP.

Cancer Res. 2010 Apr 15;70(8):3089-97. doi: 10.1158/0008-5472.CAN-09-3138.


Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathway.

Beildeck ME, Gelmann EP, Byers SW.

Exp Cell Res. 2010 Jul 1;316(11):1763-72. doi: 10.1016/j.yexcr.2010.02.001. Epub 2010 Feb 6. Review.


Primary vulvar Ewing sarcoma/primitive neuroectodermal tumor: a report of 2 cases and review of the literature.

Cetiner H, Kir G, Gelmann EP, Ozdemirli M.

Int J Gynecol Cancer. 2009 Aug;19(6):1131-6. doi: 10.1111/IGC.0b013e3181acae33. Review.


Interactions of the acidic domain and SRF interacting motifs with the NKX3.1 homeodomain.

Ju JH, Maeng JS, Lee DY, Piszczek G, Gelmann EP, Gruschus JM.

Biochemistry. 2009 Nov 10;48(44):10601-7. doi: 10.1021/bi9013374.


Cumulative incidence of false-positive results in repeated, multimodal cancer screening.

Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE.

Ann Fam Med. 2009 May-Jun;7(3):212-22. doi: 10.1370/afm.942.


Clinically relevant prognostic markers for prostate cancer: the search goes on.

Gelmann EP, Henshall SM.

Ann Intern Med. 2009 May 5;150(9):647-9. No abstract available.


Mortality results from a randomized prostate-cancer screening trial.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18. Erratum in: N Engl J Med. 2009 Apr 23;360(17):1797.


NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation.

Muhlbradt E, Asatiani E, Ortner E, Wang A, Gelmann EP.

Cancer Res. 2009 Mar 15;69(6):2615-22. doi: 10.1158/0008-5472.CAN-08-3022. Epub 2009 Mar 3.


Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.

Grubb RL 3rd, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, Weissfeld JL, Urban DA, Buys SS, Gelmann EP, Ragard LR, Crawford ED, Prorok PC, Gohagan JK, Berg CD, Andriole GL.

BJU Int. 2008 Dec;102(11):1524-30. doi: 10.1111/j.1464-410X.2008.08214.x.


Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1.

Markowski MC, Bowen C, Gelmann EP.

Cancer Res. 2008 Sep 1;68(17):6896-901. doi: 10.1158/0008-5472.CAN-08-0578.


A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.

BJU Int. 2008 May;101(9):1084-9. doi: 10.1111/j.1464-410X.2008.07509.x.


Complexities of prostate-cancer risk.

Gelmann EP.

N Engl J Med. 2008 Feb 28;358(9):961-3. doi: 10.1056/NEJMe0708703. Epub 2008 Jan 16. No abstract available.


Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.

Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT.

Cancer Res. 2008 Jan 1;68(1):236-48. doi: 10.1158/0008-5472.CAN-07-2972.


Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial.

Peters U, Leitzmann MF, Chatterjee N, Wang Y, Albanes D, Gelmann EP, Friesen MD, Riboli E, Hayes RB.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):962-8.


Genome-wide association study of prostate cancer identifies a second risk locus at 8q24.

Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G.

Nat Genet. 2007 May;39(5):645-9. Epub 2007 Apr 1.


NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity.

Bowen C, Stuart A, Ju JH, Tuan J, Blonder J, Conrads TP, Veenstra TD, Gelmann EP.

Cancer Res. 2007 Jan 15;67(2):455-64.


Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.

Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK.

BJU Int. 2007 Apr;99(4):775-9. Epub 2007 Jan 12.


Physical and functional interactions between the prostate suppressor homeoprotein NKX3.1 and serum response factor.

Ju JH, Maeng JS, Zemedkun M, Ahronovitz N, Mack JW, Ferretti JA, Gelmann EP, Gruschus JM.

J Mol Biol. 2006 Jul 28;360(5):989-99. Epub 2006 Jun 15.


Molecular biology of prostate-cancer pathogenesis.

Shand RL, Gelmann EP.

Curr Opin Urol. 2006 May;16(3):123-31. Review.


Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.

Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK.

J Urol. 2006 Apr;175(4):1286-90; discussion 1290.


Effect of homeodomain protein NKX3.1 R52C polymorphism on prostate gland size.

Rodriguez Ortner E, Hayes RB, Weissfeld J, Gelmann EP.

Urology. 2006 Feb;67(2):311-5. Epub 2006 Jan 25.


Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function.

Zheng SL, Ju JH, Chang BL, Ortner E, Sun J, Isaacs SD, Sun J, Wiley KE, Liu W, Zemedkun M, Walsh PC, Ferretti J, Gruschus J, Isaacs WB, Gelmann EP, Xu J.

Cancer Res. 2006 Jan 1;66(1):69-77.


Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor.

Song LN, Gelmann EP.

J Biol Chem. 2005 Nov 11;280(45):37853-67. Epub 2005 Sep 1.


Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence.

Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT.

Clin Cancer Res. 2005 Aug 15;11(16):5863-8.


Methods for etiologic and early marker investigations in the PLCO trial.

Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, Reding D, Gelmann EP, Rothman N, Pfeiffer RM, Hoover RN, Berg CD; PLCO Trial Team.

Mutat Res. 2005 Dec 30;592(1-2):147-54. Epub 2005 Jul 27.


The ubiquitin-proteasome pathway and its role in cancer.

Mani A, Gelmann EP.

J Clin Oncol. 2005 Jul 20;23(21):4776-89. Review.


Targeted therapies for prostate cancer.

Asatiani E, Gelmann EP.

Expert Opin Ther Targets. 2005 Apr;9(2):283-98. Review.


Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team.

J Natl Cancer Inst. 2005 Mar 16;97(6):433-8.


Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.

Asatiani E, Huang WX, Wang A, Rodriguez Ortner E, Cavalli LR, Haddad BR, Gelmann EP.

Cancer Res. 2005 Feb 15;65(4):1164-73.


Expression of genes and proteins specific for prostate cancer.

Gelmann EP, Semmes OJ.

J Urol. 2004 Nov;172(5 Pt 2):S23-6; discussion S26-7. Review.


Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.

Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW.

J Urol. 2004 Nov;172(5 Pt 2):S3-5. Review. No abstract available.


9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E.

Urol Oncol. 2004 Sep-Oct;22(5):398-403.


Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization.

Zhang Y, Glass A, Bennett N, Oyama KA, Gehan E, Gelmann EP.

Cancer. 2004 Jan 15;100(2):300-7.


Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.

Song LN, Coghlan M, Gelmann EP.

Mol Endocrinol. 2004 Jan;18(1):70-85. Epub 2003 Oct 30.


Searching for the gatekeeper oncogene of prostate cancer.

Gelmann EP.

Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S11-20. Review.


Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells.

Kimura K, Markowski M, Edsall LC, Spiegel S, Gelmann EP.

Cell Death Differ. 2003 Feb;10(2):240-8.


Expression of NKX3.1 in normal and malignant tissues.

Gelmann EP, Bowen C, Bubendorf L.

Prostate. 2003 May 1;55(2):111-7.


Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.

Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L.

Prostate. 2003 Apr 1;55(1):20-9.


Retinoblastoma protein-mediated apoptosis after gamma-irradiation.

Bowen C, Birrer M, Gelmann EP.

J Biol Chem. 2002 Nov 22;277(47):44969-79. Epub 2002 Sep 23.

Supplemental Content

Loading ...
Support Center